[Prospects for neuroprotective glaucoma therapy].
Grehn
F
F
Universitäts-Augenklinik, Josef Schneider Strasse 11, 97080 Würzburg. f.grehn@augenklinik.uni-wuerzburg.de
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology; D015784:Betaxolol / Q000627:therapeutic use; D019208:Brain-Derived Neurotrophic Factor / Q000502:physiology; D000068438:Brimonidine Tartrate; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004195:Disease Models, Animal; D015259:Dopamine Agents / Q000627:therapeutic use; D005901:Glaucoma / Q000188:drug therapy* / Q000503:physiopathology; D005902:Glaucoma, Open-Angle / Q000188:drug therapy; D000882:Haplorhini; D006801:Humans; D008559:Memantine / Q000627:therapeutic use; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D009553:Nimodipine / Q000627:therapeutic use; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D011810:Quinoxalines / Q000627:therapeutic use; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors
D000316:Adrenergic alpha-Agonists; D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D019208:Brain-Derived Neurotrophic Factor; D002121:Calcium Channel Blockers; D015259:Dopamine Agents; D018696:Neuroprotective Agents; D011810:Quinoxalines; D016194:Receptors, N-Methyl-D-Aspartate; D000068438:Brimonidine Tartrate; D009553:Nimodipine; D019001:Nitric Oxide Synthase; D015784:Betaxolol; D008559:Memantine